{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:07:07Z","timestamp":1777964827350,"version":"3.51.4"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment options for mantle cell lymphomas have expanded considerably over recent years, offering hematologists solutions for older patients with an appropriate risk-to-benefit ratio. Indeed, unfit older patients are exposed to a higher risk of toxicity with a standard treatment. Although new treatments have generally good safety profiles, they may lead to unexpected consequences in unfit older patients. Involving geriatricians and a comprehensive geriatric assessment in patient care could help hematologists address these vulnerabilities. The geriatric evaluation process is time-consuming but can be simplified, and its potential to help hematologists foresee unexpected consequences of treatment has now been demonstrated.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.425","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"425-431","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of the elderly patient with mantle cell lymphoma"],"prefix":"10.1182","volume":"2016","author":[{"given":"Pierre","family":"Soubeyran","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institut Bergoni\u00e9, Bordeaux, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Universitaire Grenoble, La Tronche, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9","key":"2019111704084468700_B1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"issue":"8","key":"2019111704084468700_B2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: a population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann Hematol"},{"issue":"8","key":"2019111704084468700_B3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111704084468700_B4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/djt104","article-title":"Geriatric oncology clinics on the rise","volume":"105","author":"McNeil","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019111704084468700_B5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111704084468700_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.05.001","article-title":"Physicians\u2019 judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy","volume":"64","author":"Wedding","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2019111704084468700_B7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"issue":"19","key":"2019111704084468700_B8","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2019111704084468700_B9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111704084468700_B10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.295.7.801","article-title":"Development and validation of a prognostic index for 4-year mortality in older adults","volume":"295","author":"Lee","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"2019111704084468700_B11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11606-009-1073-y","article-title":"Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey","volume":"24","author":"Schonberg","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"23","key":"2019111704084468700_B12","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1001\/jama.285.23.2987","article-title":"Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"issue":"15","key":"2019111704084468700_B13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2011.35.7442","article-title":"Predictors of early death risk in older patients treated with first-line chemotherapy for cancer","volume":"30","author":"Soubeyran","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111704084468700_B14","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111704084468700_B15","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"suppl","key":"2019111704084468700_B16","first-page":"S46","article-title":"Low MNA score and thrombocytopenia are predictive of unexpected hospital admission during treatment in elderly patients receiving chemotherapy","volume":"2","author":"Warkus","year":"2011","journal-title":"J Geriatr Oncol"},{"issue":"31","key":"2019111704084468700_B17","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2012.47.7430","article-title":"Functional decline in older patients with cancer receiving first-line chemotherapy","volume":"31","author":"Hoppe","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111704084468700_B18","author":"Extermann","year":"2011"},{"issue":"suppl","key":"2019111704084468700_B19","article-title":"Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project","volume":"29","author":"Soubeyran","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019111704084468700_B20","first-page":"S338","article-title":"Performance of two geriatric screening tools in older cancer patients","volume":"49","author":"Kenis","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"2019111704084468700_B21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111704084468700_B22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111704084468700_B23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":"Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"2019111704084468700_B24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ctrv.2013.01.007","article-title":"Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin\u2019s lymphoma: a systematic review","volume":"39","author":"Bellera","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"2019111704084468700_B25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","article-title":"Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry","volume":"19","author":"Hamaker","year":"2014","journal-title":"Oncologist"},{"issue":"11","key":"2019111704084468700_B26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111704084468700_B27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"2019111704084468700_B28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2019111704084468700_B29","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111704084468700_B30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111704084468700_B31","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704084468700_B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111704084468700_B33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111704084468700_B34","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1179\/102453312X13336169155970","article-title":"Metronomic therapy for refractory\/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen","volume":"17","author":"Coleman","year":"2012","journal-title":"Hematology"},{"issue":"6","key":"2019111704084468700_B35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ejca.2010.01.006","article-title":"Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?","volume":"46","author":"Pallis","year":"2010","journal-title":"Eur J Cancer"},{"key":"2019111704084468700_B36","volume-title":"Blood","author":"Gressin","year":"2014"},{"issue":"19","key":"2019111704084468700_B37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"10020","key":"2019111704084468700_B38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2019111704084468700_B39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00520-011-1127-7","article-title":"Falls in persons with chemotherapy-induced peripheral neuropathy","volume":"20","author":"Tofthagen","year":"2012","journal-title":"Support Care Cancer"},{"issue":"25","key":"2019111704084468700_B40","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111704084468700_B41","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111704084468700_B42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","volume":"22","author":"Aapro","year":"2011","journal-title":"Ann Oncol"},{"issue":"8878","key":"2019111704084468700_B43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0140-6736(93)92884-V","article-title":"Comprehensive geriatric assessment: a meta-analysis of controlled trials","volume":"342","author":"Stuck","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"2019111704084468700_B44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jgo.2013.04.007","article-title":"From suboptimal to optimal treatment in older patients with cancer","volume":"4","author":"Soubeyran","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"2019111704084468700_B45","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"2019111704084468700_B46","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/425\/1251614\/hem088374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/425\/1251614\/hem088374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:09:19Z","timestamp":1573981759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/425\/21131\/Treatment-of-the-elderly-patient-with-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.425","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}